Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
biotech
boston blog main
boston top stories
3
×
life sciences
national blog main
national top stories
third rock ventures
3
×
boston
clinical trials
new york blog main
new york top stories
startups
acetylon pharmaceuticals
ally bridge group
ambys medicines
antisense oligonucleotide
benzodiazepines
big data analytics
biogen
blackrock
blackstone group
blackstone life sciences
casdin capital
cell therapy
columbia university
constellation pharmaceuticals
david goldstein
deals
depression
diabetic nephropathy
epi4k
epilepsy
essential tremor
eventide asset management
focal segmental glomerulosclerosis
gene therapy
genentech
goldfinch bio
holger willenbring
investing
What
medicines
3
×
new
3
×
biotech
diseases
genetic
aiming
aims
ambys
analysis
backed
big
bio
bring
cause
ceo
company
control
deadly
deal
debuted
develop
drug
drugs
employing
epilepsy
formed
future
genes
goldfinch
ipo
kidney
later
launch
lead
links
liver
make
marcio
million
mutations
Language
unset
Current search:
medicines
×
photo
×
new
×
" boston top stories "
×
" third rock ventures "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?